The Opportunity: Revolution Medicines is offering a highly visible opportunity for talented and motivated individual to join our Precision Medicine Companion Diagnostics team as an Associate Director, Companion Diagnostics within the Translational Medicine function, which supports CDx development across RevMed portfolio. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development.